CVC  Novartis Venture Funds

http://www.nvfund.com/





     Office Locations:

Novartis Services, Inc.
355 Main Street, Suite 603
Cambridge, MA 02142
Phone: 617-871-3536
Fax: 617-871-7788

 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Novartis is an early-stage investor with a focus in new therapeutics & platforms, including: medical devices/implants, diagnostics/biomarkers and drug delivery/biopolymers. Novartis regionally invests in the USA/Canada, Europe, Switzerland and Asia/Pacific. The firm currently manages more than $800 million across all of its funds. Novartis Venture Funds makes investments through three investment vehicles: the Novartis Venture Fund, the Novartis Option Fund and the Korea Fund. Novartis anticipates its larger investments will range up to $15 - 20 million per company over its life, but these investments can be as little as $100,000 to get started. The venture fund is stage-agnostic and engages in seed investments as well as later-stage investments. The firm will increase its activities to lead or co-lead deals and remains open to participating in larger syndicates. The Novartis Option Fund's to seed innovative startup companies during their earliest stages. The Novartis Option Fund has an initial size of $200M. In 2008, Novartis Venture Funds created the Novartis Korea Venture Fund, a unique commitment to early-stage investing in innovative life sciences companies. In 2011, Novartis increased its portfolio by seven new investments and now comprises over 65 companies, making NVF one of the world's largest and most active corporate life sciences venture funds. Including the commitment of other investors, over $2 billion is invested in NVF portfolio companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Dr. Aaron Nelson Principal
    Dr. Beat Steffan Principal
    Dr. Campbell Murray Managing Director
    Dr. Florian Muellershausen Principal
    Dr. Lauren Silverman Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      04/02/2018


      Macrolide Pharmaceuticals


      MA


      $20,000,000


      


      01/03/2018


      Expansion Therapeutics


      CA


      $55,300,000


      Series A


      01/02/2018


      PEAR Therapeutics


      MA


      $50,000,000


      Series B


      10/18/2017


      Blade Therapeutics


      CA


      $45,000,000


      Series B


      09/13/2017


      Rani Therapeutics


      CA


      $39,000,000


      Series D


      07/24/2017


      Effector Therapeutics


      CA


      $38,600,000


      Series C


      07/20/2017


      NeuroVia


      MA


      $14,000,000


      Series A


      07/12/2017


      E-Scape Bio


      CA


      $63,000,000


      Series A Extension


      05/22/2017


      Lemonaid Health


      CA


      $11,000,000


      Series A


     

    Portfolio companies include:


      Adicet Bio


      Advanced Animal Diagnostics
        web link


      Aeglea Biotherapeutics
        web link


      Aerpio Therapeutics
        web link


      Aileron Therapeutics
        web link


      Akebia Therapeutics
        web link


      Alios BioPharma
        web link


      AMP Therapeutics
        web link


      Annexon Bioscience
        web link


      Annexon Biosciences
        web link


      Atlas Genetics
        web link


      Autonomic Technologies
        web link


      Bicycle Therapeutics
        web link


      BioCure
        web link


      BioNano Genomics
        web link


      Blade Therapeutics
        web link


      C4 Therapeutics
        web link


      Caribou Biosciences
        web link


      Catalyst Biosciences
        web link


      Cavion
        web link


      Celladon
        web link


      Cequent Pharmaceuticals
        web link


      Covagen
        web link


      Cylene Pharmaceuticals
        web link


      Destiny Pharma
        web link


      Diagnoplex Biosciences
        web link


      E-Scape Bio
        web link


      Effector Therapeutics
        web link


      Evolva
        web link


      Expansion Therapeutics
        web link


      Galera Therapeutics
        web link


      Genedata
        web link


      Heptares Therapeutics
        web link


      IFM Therapeutics
        web link


      ImaginAb
        web link


      Innocrin Pharmaceuticals
        web link


      Intellia Therapeutics
        web link


      Lemonaid Health
        web link


      Macrolide Pharmaceuticals
        web link


      Merganser Biotech
        web link


      Merus Biopharmaceuticals
        web link


      Neomics
        web link


      Neurovance
        web link


      NeuroVia


      Okairos
        web link


      PEAR Therapeutics
        web link


      Polyphor
        web link


      Proteus Digital Health
        web link


      Quartet Medicine
        web link


      Qurient Therapeutics
        web link


      Ra Pharmaceuticals
        web link


      Rani Therapeutics
        web link


      Raze Therapeutics
        web link


      ROX Medical
        web link


      Seventh Sense Biosystems
        web link


      Sorbent Therapeutics
        web link


      Thesan Pharmaceuticals
        web link


      Trellis Bioscience
        web link


     

    Recent News:


      There is no recent news for Novartis Venture Funds.